

35. Borrelli S, Matarazzo I, Lembo E, et al. Chronic Hyperkalemia in Chronic Kidney Disease: An Old Concern with New Answers. *Int J Mol Sci.* 2022;23(12):6378.
36. Ramirez-Sandoval JC, Madero M. Treatment of Hyperuricemia in Chronic Kidney Disease. *Contrib Nephrol.* 2018;192: 135-146.
37. Lim YJ, Sidor NA, Toniai NC, et al. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets. *Toxins (Basel).* 2021;13(2):142.
38. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. *Kidney Int.* 2017;92(1):26-36.
39. Evenepoel P, Stenvinkel P, Shanahan C, et al. Inflammation and gut dysbiosis as drivers of CKD-MBD. *Nat Rev Nephrol.* 2023;19(10):646-657.
40. Yamada S, Nakano T. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. *J Atheroscler Thromb.* 2023;30(8):835-850.
41. Pazianas M, Miller PD. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. *Am J Kidney Dis.* 2021;78(4):582-589.
42. Rosner MH, Reis T, Husain-Syed F, et al. Classification of Uremic Toxins and Their Role in Kidney Failure. *Clin J Am Soc Nephrol.* 2021;16(12):1918-1928.
43. Sternlicht H, Bakris GL. The Kidney in Hypertension. *Med Clin North Am.* 2017;101(1):207-217.
44. Ameer OZ. Hypertension in chronic kidney disease: What lies behind the scene. *Front Pharmacol.* 2022; 13:949260.
45. Park CH, Kim HW, Joo YS, et al; KNOW-CKD (Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators. Findings from the KNOW-CKD study indi-

cate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression. *Kidney Int.* 2024;105(4):835-843.

46. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens.* 2023;41(12):1874-2071.

47. Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. *Kidney Int.* 2024;105(4):684-701.

48. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int.* 2021;99(3S):S1-S87.

# Urologie pro praxi na rok 2024

## Už máte předplaceno?



**PŘEDPLATNÝM  
ČASOPISU  
NA ROK 2024  
ZÍSKÁTE**

**4 čísla ve vaší schránce**

**Tematická suplementa**

**Čtení na tabletech,  
PC a telefonech**

**Přístup do archivu  
časopisu on-line**

**Cena předplatného  
na rok 2024: 1 100 Kč**

**OBJEDNÁVEJTE**

**[www.onkologיעs.cz](http://www.onkologיעs.cz)**

**[předplatne@solen.cz](mailto:předplatne@solen.cz)**

**585 204 335**

